List of Excipients in Branded Drug ALPHAGAN P

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	ALPHAGAN P	brimonidine tartrate	0023-9321	BORIC ACID
Allergan Inc	ALPHAGAN P	brimonidine tartrate	0023-9321	CALCIUM CHLORIDE
Allergan Inc	ALPHAGAN P	brimonidine tartrate	0023-9321	CARBOXYMETHYLCELLULOSE SODIUM
Allergan Inc	ALPHAGAN P	brimonidine tartrate	0023-9321	HYDROCHLORIC ACID
Allergan Inc	ALPHAGAN P	brimonidine tartrate	0023-9321	MAGNESIUM CHLORIDE

ALPHAGAN P Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

ALPHAGAN P is a brimonidine tartrate ophthalmic solution differentiated by its low-dose formulation, Purite oxidative preservative system, sodium carboxymethylcellulose viscosity modifier, and reduced exposure to benzalkonium chloride. The commercial opportunity is concentrated in preservative-free ophthalmic products, improved tolerability, combination therapies, specialty generics, and alternative delivery systems rather than in the original branded formulation.

What is ALPHAGAN P and how does its formulation work?

ALPHAGAN P is a prescription ophthalmic product containing brimonidine tartrate, an alpha-2 adrenergic receptor agonist used to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The product is marketed in 0.1% and 0.15% strengths, with dosing generally administered three times daily. [1]

The formulation strategy addresses two commercial and clinical problems:

1. Brimonidine must be delivered repeatedly to the ocular surface.
2. Chronic exposure to conventional preservatives can contribute to ocular-surface irritation and intolerance.

ALPHAGAN P uses Purite, a stabilized oxychloro complex, as the preservative system. Purite breaks down after administration into components that are present naturally in the tear film, including chloride ions, water and oxygen-related species. The product also contains sodium carboxymethylcellulose, which increases viscosity and can improve ocular residence time.

ALPHAGAN P formulation composition

Component	Function in formulation
Brimonidine tartrate	Active pharmaceutical ingredient
Purite, stabilized oxychloro complex	Preservative system
Sodium carboxymethylcellulose	Viscosity modifier and retention aid
Boric acid and sodium borate	Buffer system
Sodium chloride	Tonicity adjustment
Hydrochloric acid or sodium hydroxide	pH adjustment
Purified water	Vehicle

The product is formulated at an ophthalmically acceptable pH and osmolality. The exact formulation and manufacturing controls are part of the approved product record and may not be fully disclosed in public labeling. [1][2]

What excipients protect the commercial position of ALPHAGAN P?

The strongest formulation differentiator is the combination of Purite and sodium carboxymethylcellulose. Neither excipient is inherently exclusive, but their use in a specific brimonidine formulation can create regulatory, manufacturing and performance barriers.

Purite as a preservative strategy

Purite allows ALPHAGAN P to avoid benzalkonium chloride, a widely used ophthalmic preservative associated with ocular-surface toxicity and discomfort in some chronic-use patients. This gives the product a tolerability-based positioning against older brimonidine 0.2% products and other preserved glaucoma drops.

The commercial value of Purite depends on four factors:

• Preservative efficacy across the product shelf life.
• Compatibility with brimonidine tartrate and packaging materials.
• Control of degradation products.
• Demonstration that the formulation remains sterile after repeated use.

Purite is not a simple drop-in replacement for benzalkonium chloride. It requires formulation-specific control of pH, ionic strength, container compatibility and preservative performance. These controls can make generic replication more difficult even when the active ingredient is well established.

Sodium carboxymethylcellulose as a retention and comfort excipient

Sodium carboxymethylcellulose increases viscosity and may improve the time the solution remains on the ocular surface. It can support dose retention and reduce the sensation of rapid washout through the nasolacrimal system.

Its concentration must be balanced against:

• Blurring immediately after administration.
• Drop size and dispensing behavior.
• Mixing uniformity.
• Sterilizing filtration.
• Patient comfort.
• Container closure performance.

The excipient therefore has both pharmacotechnical and commercial importance. A generic that uses a different viscosity modifier may match the brimonidine strength but fail to replicate the same ocular feel, retention profile or patient preference.

How does ALPHAGAN P compare with older brimonidine formulations?

Product type	Typical strength	Preservative approach	Commercial positioning
ALPHAGAN P	0.1% or 0.15%	Purite	Lower-dose, preservative-differentiated prescription product
Older brimonidine products	Commonly 0.2%	Often benzalkonium chloride	Established, lower-cost glaucoma therapy
Brimonidine generics	Varies by product	Product-specific	Price competition and formulary access
Brimonidine 0.025%, LUMIFY	0.025%	Product-specific OTC formulation	Ocular redness reduction, not glaucoma treatment
Preservative-free brimonidine candidates	Usually 0.1% or 0.15%	Unit-dose or alternative system	Ocular-surface tolerability and chronic-use positioning

ALPHAGAN P is not interchangeable with LUMIFY. LUMIFY contains a much lower concentration of brimonidine tartrate and is approved for the temporary relief of ocular redness. ALPHAGAN P is a prescription product for reduction of intraocular pressure. The two products rely on the same active moiety but occupy different regulatory, dosing and commercial categories. [1][3]

What patents protect ALPHAGAN P and when did exclusivity end?

The principal composition and ophthalmic-use patents associated with brimonidine and early brimonidine formulations were filed during the 1980s and 1990s. Those foundational rights have expired or reached the end of their ordinary United States patent terms.

The commercial exclusivity profile is therefore primarily determined by:

• Expired active-ingredient and early formulation patents.
• Any later formulation or preservative patents listed for the specific product.
• FDA regulatory exclusivity.
• ANDA approval timing.
• Product-specific bioequivalence and labeling requirements.

The original branded product does not retain a durable monopoly solely because it uses Purite or carboxymethylcellulose. A later patent would need to claim a novel formulation, manufacturing process, container system, preservative concentration, stability profile or therapeutic method that meets patentability and enforcement requirements.

Orange Book status and listed patents

The FDA Orange Book is the controlling source for current patent and exclusivity listings associated with an approved NDA. ALPHAGAN P is associated with an FDA-approved brimonidine tartrate ophthalmic solution NDA. Current patent listings should be assessed by product strength, NDA, patent-use code and listing status rather than by the ALPHAGAN P brand name alone. [4]

A commercial diligence review should distinguish between:

• Patents listed against the 0.1% product.
• Patents listed against the 0.15% product.
• Method-of-use patents.
• Formulation patents.
• Device or container patents.
• Patents that have expired, been delisted or are no longer blocking.

No durable patent moat should be assumed from the Purite name alone. The key risk is whether a specific branded formulation patent remains listed and whether an ANDA applicant has made a Paragraph IV certification.

Which companies are challenging ALPHAGAN P with generic products?

Brimonidine ophthalmic products have been subject to generic competition because the active ingredient is well characterized and the major early patent barriers have expired. Generic manufacturers have pursued brimonidine tartrate ophthalmic solutions in multiple strengths, including products positioned against 0.15% and 0.2% formulations.

Potential competitors include established ophthalmic generic suppliers such as:

• Apotex.
• Bausch + Lomb.
• Sandoz.
• Teva.
• Akorn, subject to its changing corporate and commercial status.
• Other FDA-authorized ophthalmic manufacturers and contract manufacturers.

The competitive field changes by strength, dosage form, preservative system and approved labeling. A company may compete with a 0.2% preserved product without directly substituting for ALPHAGAN P 0.1% or 0.15%.

Paragraph IV and generic launch risk

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. If the NDA holder sues within the statutory period, FDA approval may be subject to a stay of up to 30 months, subject to litigation developments and applicable statutory rules. [5]

For ALPHAGAN P, the principal generic launch risks are likely to arise from:

• A formulation patent covering the low-dose product.
• A preservative-system patent.
• A method-of-use patent with an applicable patent-use code.
• A patent covering a container or multidose dispensing system.
• A failure to demonstrate equivalent preservative effectiveness or stability.

The absence of an active blocking patent does not eliminate technical risk. Ophthalmic solutions require sterile manufacturing, low particulate levels, container integrity and reliable drop delivery. These requirements can delay approval even where patent barriers are weak.

What formulation patents and manufacturing barriers matter most?

The most valuable IP around an ALPHAGAN P-type product is likely to reside in formulation implementation rather than in the brimonidine molecule.

High-value technical claim areas

Potential claim areas include:

• Brimonidine concentration ranges.
• Purite concentration and degradation behavior.
• Buffer composition and pH range.
• Sodium carboxymethylcellulose concentration.
• Preservative efficacy after repeated opening.
• Stability under accelerated and long-term conditions.
• Low-impurity manufacturing processes.
• Multidose container and closure systems.
• Reduced ocular-surface irritation.
• Combination formulations with other glaucoma agents.

Manufacturing know-how can be more commercially important than a narrow patent. Purite-containing formulations require control of oxidative species and compatibility with plastic packaging. Brimonidine degradation, discoloration, pH drift and preservative loss can affect shelf life and batch release.

Geographic coverage

United States commercial protection is assessed through FDA Orange Book listings, United States patents and FDA approval status. European protection depends on national validation, supplementary protection certificates where applicable, and national regulatory exclusivity. Canada, Japan, China, South Korea and emerging markets require separate patent and registration reviews.

A formulation that is commercially unprotected in the United States may still face active rights in selected foreign jurisdictions. Conversely, a patent estate may have limited value in countries where procurement is dominated by hospital tenders and low-price generic substitution.

What commercial opportunities exist for ALPHAGAN P excipient technology?

Preservative-free brimonidine

The clearest opportunity is a preservative-free brimonidine product for patients with ocular-surface disease, chronic topical exposure or intolerance to preserved glaucoma drops. Commercial formats include:

• Unit-dose polyethylene ampoules.
• Multidose preservative-free pump systems.
• Sterile blow-fill-seal containers.
• Refillable or low-contamination dispensing devices.

A preservative-free product would need to justify its higher cost through improved tolerability, adherence or persistence. Unit-dose packaging can increase manufacturing and logistics costs, while multidose systems create device and sterility-control requirements.

Brimonidine combinations

Brimonidine can be combined with other intraocular-pressure-lowering agents, including timolol, dorzolamide or prostaglandin analogues. Combination products reduce bottle burden and may improve adherence. Their commercial value depends on:

• Compatibility of the active ingredients.
• Preservative strategy.
• pH and buffer requirements.
• Stability of each active ingredient.
• Comparable dosing schedules.
• Freedom to operate around combination patents.

A low-irritation preservative system could differentiate a combination product in patients using several chronic ophthalmic medications.

Improved delivery systems

The active ingredient is suitable for opportunities involving:

• Smaller drop volumes.
• Metered-dose delivery.
• Sustained ocular-surface residence.
• Reduced nasolacrimal drainage.
• Contact-lens-compatible formulations.
• In situ gel systems.
• Ocular inserts or depot technologies.

The commercial challenge is that more complex delivery systems raise regulatory requirements and may require clinical evidence beyond conventional solution bioequivalence.

Specialty generic positioning

A generic manufacturer can compete through a formulation that matches the branded product’s low-dose and preservative profile rather than competing only on price. A product with:

• Purite or a validated alternative preservative system.
• A similar viscosity profile.
• A comfortable drop sensation.
• Reliable multidose delivery.
• Strong pharmacy and payer access.

could command better share than a conventional preserved generic, especially in ophthalmology practices that manage chronic ocular-surface symptoms.

What FDA regulatory issues affect new ALPHAGAN P-type products?

A conventional brimonidine ophthalmic solution would generally be developed through an ANDA if the applicant can demonstrate pharmaceutical equivalence and bioequivalence to a relevant reference product. The FDA review will focus on active ingredient, strength, dosage form, route, inactive ingredients, sterility, container closure and labeling. [5]

A materially different excipient system may create additional regulatory complexity. The applicant may need to address:

• Comparative preservative effectiveness.
• In vitro performance.
• Drop size and delivered volume.
• Ocular irritation and sensitization.
• Stability and degradation products.
• Container interaction.
• Microbiological integrity during in-use storage.
• Comparative clinical tolerability.

A novel delivery system or a new therapeutic claim may require a 505(b)(2) pathway rather than a conventional ANDA. The pathway depends on the extent of reliance on the reference product and the differences in formulation, device or clinical use.

How strong is the ALPHAGAN P patent estate?

The patent estate is likely moderate to weak for the basic brimonidine ophthalmic concept because the active ingredient, glaucoma indication and conventional solution dosage form are mature technologies. Its relative strength improves where claims cover:

• A narrowly defined Purite formulation.
• Specific preservative concentrations.
• Stability or degradation control.
• A novel dispensing device.
• A combination product.
• A demonstrable tolerability advantage.
• A process that is difficult to design around.

The principal commercial defense is therefore a layered strategy combining formulation patents, device patents, regulatory data, manufacturing know-how, physician familiarity and payer contracting.

What revenue exposure exists from generic ALPHAGAN P entry?

Generic entry can reduce branded revenue through price erosion, formulary substitution and pharmacy-level switching. Exposure depends on the degree to which ALPHAGAN P prescriptions are driven by:

• Preservative sensitivity.
• Physician preference.
• Insurance coverage.
• Availability of a true low-dose equivalent.
• Patient adherence and refill persistence.
• Availability of preservative-free alternatives.

A generic 0.2% brimonidine product is not a complete commercial substitute for ALPHAGAN P. The highest exposure arises when a competing product matches the 0.1% or 0.15% strength and provides a comparable low-irritation formulation.

What generic launch scenarios exist for ALPHAGAN P?

Scenario	Likely market effect
Conventional preserved generic launches first	Rapid price pressure, with incomplete substitution among intolerant patients
Low-dose generic with similar excipients	Higher branded share loss and stronger pharmacy substitution
Preservative-free competitor launches	Premium segment erosion and physician switching
Combination brimonidine product expands	Reduced bottle burden and pressure on standalone demand
Device-based product gains approval	Differentiation through dosing consistency and tolerability
No direct 0.1% or 0.15% equivalent	Continued niche value for the branded formulation

Key Takeaways

• ALPHAGAN P uses brimonidine tartrate with Purite and sodium carboxymethylcellulose to support a lower-preservative-burden, chronic-use ophthalmic formulation.
• The active ingredient and basic ophthalmic use are mature and exposed to generic competition.
• The main defensible assets are formulation implementation, preservative performance, stability, packaging and manufacturing know-how.
• A preservative-free or multidose low-contamination brimonidine product is the strongest adjacent commercial opportunity.
• Combination products and improved delivery devices can create new differentiation, but they carry higher regulatory and development costs.
• Generic risk is highest from a product matching ALPHAGAN P strength, formulation tolerability and approved indication.
• Orange Book listings, patent-use codes and current FDA approval records must be reviewed by NDA and strength before any launch or litigation conclusion.

FAQs About ALPHAGAN P Excipient Strategy

Is Purite in ALPHAGAN P the same as benzalkonium chloride?

No. Purite is a stabilized oxychloro complex, while benzalkonium chloride is a quaternary ammonium preservative. Their chemistry, ocular-surface profile and formulation controls differ.

Can a generic brimonidine product use different excipients from ALPHAGAN P?

Yes, subject to FDA requirements. The generic must meet applicable pharmaceutical equivalence, bioequivalence, quality, sterility, stability and labeling requirements.

Is ALPHAGAN P preservative-free?

No. ALPHAGAN P uses Purite as a preservative system. It is differentiated from many conventional products that use benzalkonium chloride, but it is not a preservative-free product.

Does LUMIFY compete directly with ALPHAGAN P?

No. LUMIFY contains a lower brimonidine concentration and is marketed for temporary relief of ocular redness. ALPHAGAN P is a prescription glaucoma product used to lower intraocular pressure.

What is the most attractive new product opportunity based on ALPHAGAN P technology?

A preservative-free or low-contamination multidose brimonidine product with validated ocular-surface tolerability has the strongest commercial rationale. A combination product with a reduced preservative burden is the next most credible opportunity.

References

1. U.S. Food and Drug Administration. (2024). ALPHAGAN P (brimonidine tartrate ophthalmic solution) prescribing information.
2. National Library of Medicine. (2024). DailyMed: ALPHAGAN P brimonidine tartrate ophthalmic solution.
3. U.S. Food and Drug Administration. (2024). LUMIFY brimonidine tartrate ophthalmic solution labeling.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: ANDA and Paragraph IV certification guidance.